Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) was the target of some unusual options trading activity on Tuesday. Traders purchased 87,937 put options on the stock. This is an increase of about 196% compared to the usual volume of 29,719 put options.
Wall Street analysts comment
Several equities analysts have recently commented on TEVA shares. Bank of America increased their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price target (was $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and issued a $20.00 price target for the company in a research note on Wednesday, July 10. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong buy” rating in a report on Saturday, August 3. Two equities analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.
Read our latest report on TEVA
Share price development of Teva Pharmaceutical Industries
NYSE TEVA shares opened at $17.14 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $8.06 and a 52-week high of $18.02. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market cap of $19.41 billion, a price-to-earnings ratio of -41.79, a PEG ratio of 1.51 and a beta of 0.90. The company has a 50-day moving average of $16.82 and a 200-day moving average of $14.99.
Insider activities at Teva Pharmaceutical Industries
In related news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares of the company’s stock, valued at $16,706,430. The sale was disclosed in a filing with the Securities & Exchange Commission, available at this link. In related news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a filing with the SEC, which is available through the SEC’s website. Also, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. The disclosure regarding this sale can be found here. 0.55% of the shares are currently owned by insiders.
Institutional investors comment on Teva Pharmaceutical Industries
Several institutional investors have recently changed their holdings in TEVA. Lingotto Investment Management LLP increased its holdings in Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock valued at $359,738,000 after purchasing an additional 607,800 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 7.1% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after purchasing an additional 2,188,212 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after acquiring an additional 1,860,000 shares in the last quarter. Sound Shore Management Inc. CT increased its stake in shares of Teva Pharmaceutical Industries by 12.6% in the 4th quarter. Sound Shore Management Inc. CT now owns 8,919,234 shares of the company’s stock valued at $93,117,000 after acquiring an additional 998,522 shares during the same period. Finally, Renaissance Technologies LLC increased its stake in shares of Teva Pharmaceutical Industries by 13.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after acquiring an additional 1,031,400 shares in the last quarter. 54.05% of the shares are owned by hedge funds and other institutional investors.
Company profile of Teva Pharmaceutical Industries
(Get free report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets and distributes generic, specialty and biopharmaceutical products in North America, Europe, Israel and worldwide. The company offers generic drugs in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams; sterile products, hormones, high potency drugs and cytotoxic agents in parenteral and solid dosage forms; and generics with medical devices and combination products.
More information
Get daily news and reviews about Teva Pharmaceutical Industries – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.
